454 related articles for article (PubMed ID: 25608772)
1. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
2. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
3. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
[TBL] [Abstract][Full Text] [Related]
4. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
Cornelissen R; Lievense LA; Maat AP; Hendriks RW; Hoogsteden HC; Bogers AJ; Hegmans JP; Aerts JG
PLoS One; 2014; 9(9):e106742. PubMed ID: 25192022
[TBL] [Abstract][Full Text] [Related]
5. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
[TBL] [Abstract][Full Text] [Related]
6. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
Alchami FS; Attanoos RL; Bamber AR
J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
[TBL] [Abstract][Full Text] [Related]
8. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
9. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma.
Iwanami T; Uramoto H; Nakagawa M; Shimokawa H; Yamada S; Kohno K; Tanaka F
Oncology; 2014; 86(2):109-16. PubMed ID: 24457449
[TBL] [Abstract][Full Text] [Related]
11. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
12. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
14. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
15. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
17. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.
Habougit C; Trombert-Paviot B; Karpathiou G; Casteillo F; Bayle-Bleuez S; Fournel P; Vergnon JM; Tiffet O; Péoc'h M; Forest F
Virchows Arch; 2017 Jun; 470(6):639-646. PubMed ID: 28349237
[TBL] [Abstract][Full Text] [Related]
18. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
20. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]